register

News - MedTech & Diagnostics

First urologist implants novel device in relieving incontinence from prostate surgery

Health Industry Hub | February 1, 2022 |

MedTech News: A novel procedure aims to restore quality of life in Australian men who suffer incontinence issues.

Insertion of an advanced artificial urinary sphincter can relieve stress incontinence caused by weakened or damaged muscles that control urination, which is a common side effect of prostate surgery.

Greenslopes Private Hospital urologist Associate Professor Eric Chung is the first surgeon in the Southern Hemisphere to insert the Rigicon ContiClassic medical device.

“Once patients with incontinence issues are fitted with an artificial urinary sphincter, they’re no longer constrained by incontinence pads and can exercise and undertake normal social interactions without the fear of wet pants or malodorous smell,” A/Prof Chung said.

You may also like: MTAA CEO unveils policy and advocacy focus for 2022

“The Rigicon ContiClassic device provides the surgeon the ability to individualise antibiotics selection, offers more cuff-size choices and makes an easier connection between the device components compared to other urinary sphincter devices on the market.”

Urinary incontinence is more common with women, but also affects up to 10% of Australian men.

A/Prof Chung performed the first ContiClassic procedure at the Brisbane hospital – part of the Ramsay Health Care group – on a 69-year-old man who developed urinary incontinence following a radical prostatectomy.

“It’s an honour to be the first surgeon in Australia and the Southern hemisphere to use this artificial urinary sphincter,” he said.

“I believe, as a surgeon, we need to continue to stay at the forefront of technology so we can offer our patients suffering from urinary incontinence the most effective options to regain continence and quality of life.”

In 2021, Rigicon announced the Therapeutic Goods Administration (TGA) approval of their prosthetic urology portfolio including the Conti Artificial Urinary Sphincter Models. According to the company, with this approval, Rigicon becomes the first medical device solutions provider in the Australian market with a diverse portfolio of men’s health treatment options.


News - MedTech & Diagnostics

Roche unlocks new horizons for genomic research in Asia Pacific

Roche unlocks new horizons for genomic research in Asia Pacific

Health Industry Hub | November 9, 2026 |

Roche is advancing its next-generation sequencing (NGS) ambitions in Asia Pacific following the global launch of AXELIOS 1 in June […]

More


News - Pharmaceuticals

'Unexpected and Surprising': Novartis’ Lp(a) setback raises tough questions for Amgen and Lilly - Professor Stephen Nicholls, Victorian Heart Hospital

‘Unexpected and surprising’: Novartis Lp(a) setback raises tough questions for Amgen and Lilly

Health Industry Hub | November 9, 2026 |

The failure of Novartis’ lipoprotein(a) [Lp(a)] therapy to translate substantial biomarker reductions into meaningful cardiovascular benefits has been met with […]

More


News - MedTech & Diagnostics

More public hospitals turn to same-day hip and knee surgery but recovery risks persist

More public hospitals turn to same-day hip and knee surgery, but key blind spots persist

Health Industry Hub | November 9, 2026 |

Same-day hip and knee replacements to ease surgical waiting lists are being trialled at The Royal Adelaide Hospital (RAH), but […]

More


News - Pharmaceuticals

TGA approves oral Wegovy, prompting questions over efficacy and clinical positioning

TGA approves oral Wegovy, prompting questions over efficacy and clinical positioning

Health Industry Hub | November 9, 2026 |

The Therapeutic Goods Administration (TGA) approval of Novo Nordisk’s oral GLP-1 receptor agonist Wegovy (semaglutide) is introducing a new dimension to […]

More


This content is copyright protected. Please subscribe to gain access.